

Tumour Treating Fields BNOS survey result

Introduction

The BNOS clinical committee commissioned a survey of members in May 2025 following letters from BNOS to NICE regarding NICE's reluctance to review tumour treating fields (TTF) as a potential treatment option for patients with brain tumours. The aim was to examine the views of the BNOS membership as to the clinical effectiveness of TTF.

Method

An anonymous survey was sent to BNOS members through the BNOS mailing platform in May 2025. The survey was linked to a recent review on the BNOS website of the evidence for tumour treating fields. Responses were collated.

Results

44 responses were received (oncology 19, neurosurgery 18, non-clinical 7) of which 28 (64%) of the clinical responses were at the consultant / professor level, and only one of those no longer treated patients (retired). Responses were evenly distributed between the North, mid, and South of England. There were 3 responses from Scotland and 2 from Wales.

Questions

There were 3 questions asked and a space for comments.

Q1. Do you believe the evidence supports a role of tumour treating fields in the treatment of patients with glioblastoma or grade 4 astrocytoma?

Yes	33 (75%)
No or limited benefit	3 (7%)
Don't know	6 (14%)
limited evidence / value	2 (4%)

Q2. Do you think tumour treating fields should be available for appropriate UK patients on the NHS (cost allowing)?

Yes	36 (82%)
No	4 (9%)
Don't Know	4 (9%)

Q3. Do you think NICE should review the technology and engage with the company to assess cost effectiveness?

Yes	42 (95.4%)
No	1 (2.3%)
Don't Know	1 (2.3%)

Comments

There were a range of comments.

6 comments supporting tumour treating field use in UK patients

5 comments questioning the evidence and / or the cost value

4 comments supporting a NICE review